This finding may be of clinical relevance due to the recent development of opevesostat (formerly MK-5684, or ODM-208), an oral selective inhibitor of CYP11A1, which has shown preliminary evidence of clinical activity in patients with antiandrogen-refractory, metastatic castration-resistant PC (mCRPC) (11). The gene discussed is CYP11A1; the disease is pachyonychia congenita.